Войти в систему Зарегистрироваться бесплатно

NeuroVive Pharmaceutical AB Доход Q / Q

Что обозначает Доход Q / Q в NeuroVive Pharmaceutical AB?

Доход Q / Q NeuroVive Pharmaceutical AB является -63.53%

Какое определение для Доход Q / Q?

Квартальный рост выручки в годовом исчислении - это увеличение дохода компании по сравнению с показателями соответствующего квартала предыдущего года, выраженными в процентах.

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Доход Q / Q компаний в Health Care сектор на OTC по сравнению с NeuroVive Pharmaceutical AB

Что делает NeuroVive Pharmaceutical AB?

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Компании с доход q / q похож на NeuroVive Pharmaceutical AB